Opthea Ltd (OPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Opthea Ltd (OPT) has a cash flow conversion efficiency ratio of 0.460x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-92.00 Million ≈ $-65.10 Million USD) by net assets (AU$-200.16 Million ≈ $-141.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Opthea Ltd - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Opthea Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OPT total liabilities for a breakdown of total debt and financial obligations.
Opthea Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Opthea Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Wantong Technology Co Ltd
SHE:002331
|
-0.056x |
|
TTY Biopharm Co Ltd
TWO:4105
|
0.097x |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
0.019x |
|
Beijing Quanshi World Online Net
SHE:002995
|
-0.109x |
|
Audax Renovables S.A.
MC:ADX
|
0.225x |
|
DXN HOLDINGS BHD.
KLSE:5318
|
0.041x |
|
UE Furniture Co Ltd
SHG:603600
|
0.098x |
|
Jinhua Chunguang Technology Co Ltd
SHG:603657
|
0.121x |
Annual Cash Flow Conversion Efficiency for Opthea Ltd (1991–2025)
The table below shows the annual cash flow conversion efficiency of Opthea Ltd from 1991 to 2025. For the full company profile with market capitalisation and key ratios, see Opthea Ltd (OPT) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$-201.07 Million ≈ $-142.27 Million |
AU$-158.64 Million ≈ $-112.25 Million |
0.789x | -62.85% |
| 2024-06-30 | AU$-75.81 Million ≈ $-53.64 Million |
AU$-161.02 Million ≈ $-113.93 Million |
2.124x | -89.58% |
| 2023-06-30 | AU$-8.79 Million ≈ $-6.22 Million |
AU$-179.30 Million ≈ $-126.87 Million |
20.391x | +1546.31% |
| 2022-06-30 | AU$69.77 Million ≈ $49.37 Million |
AU$-98.37 Million ≈ $-69.60 Million |
-1.410x | -316.10% |
| 2021-06-30 | AU$180.20 Million ≈ $127.50 Million |
AU$-61.06 Million ≈ $-43.20 Million |
-0.339x | -166.36% |
| 2020-06-30 | AU$64.81 Million ≈ $45.86 Million |
AU$-8.24 Million ≈ $-5.83 Million |
-0.127x | +83.63% |
| 2019-06-30 | AU$31.12 Million ≈ $22.02 Million |
AU$-24.19 Million ≈ $-17.11 Million |
-0.777x | -48.80% |
| 2018-06-30 | AU$38.17 Million ≈ $27.01 Million |
AU$-19.94 Million ≈ $-14.11 Million |
-0.522x | -370.79% |
| 2017-06-30 | AU$54.49 Million ≈ $38.56 Million |
AU$-6.05 Million ≈ $-4.28 Million |
-0.111x | +54.86% |
| 2016-06-30 | AU$14.98 Million ≈ $10.60 Million |
AU$-3.68 Million ≈ $-2.60 Million |
-0.246x | +18.54% |
| 2015-06-30 | AU$16.66 Million ≈ $11.79 Million |
AU$-5.03 Million ≈ $-3.56 Million |
-0.302x | +28.69% |
| 2014-06-30 | AU$9.87 Million ≈ $6.98 Million |
AU$-4.17 Million ≈ $-2.95 Million |
-0.423x | +1.23% |
| 2013-06-30 | AU$13.10 Million ≈ $9.27 Million |
AU$-5.61 Million ≈ $-3.97 Million |
-0.428x | -23.41% |
| 2012-06-30 | AU$20.67 Million ≈ $14.62 Million |
AU$-7.17 Million ≈ $-5.08 Million |
-0.347x | +14.02% |
| 2011-06-30 | AU$23.32 Million ≈ $16.50 Million |
AU$-9.42 Million ≈ $-6.66 Million |
-0.404x | -44.72% |
| 2010-06-30 | AU$27.04 Million ≈ $19.13 Million |
AU$-7.54 Million ≈ $-5.34 Million |
-0.279x | -32.46% |
| 2009-06-30 | AU$31.29 Million ≈ $22.14 Million |
AU$-6.59 Million ≈ $-4.66 Million |
-0.211x | -475.98% |
| 2008-06-30 | AU$49.18 Million ≈ $34.80 Million |
AU$-1.80 Million ≈ $-1.27 Million |
-0.037x | -105.73% |
| 2007-06-30 | AU$51.71 Million ≈ $36.59 Million |
AU$32.97 Million ≈ $23.33 Million |
0.638x | +1028.75% |
| 2006-06-30 | AU$42.07 Million ≈ $29.77 Million |
AU$-2.89 Million ≈ $-2.04 Million |
-0.069x | -20.11% |
| 2005-06-30 | AU$28.63 Million ≈ $20.26 Million |
AU$-1.64 Million ≈ $-1.16 Million |
-0.057x | +2.50% |
| 2004-06-30 | AU$29.15 Million ≈ $20.63 Million |
AU$-1.71 Million ≈ $-1.21 Million |
-0.059x | -31.10% |
| 2002-06-30 | AU$23.28 Million ≈ $16.47 Million |
AU$-1.04 Million ≈ $-736.53K |
-0.045x | -7.66% |
| 2001-06-30 | AU$24.20 Million ≈ $17.12 Million |
AU$-1.01 Million ≈ $-711.19K |
-0.042x | +87.30% |
| 1997-06-30 | AU$5.32 Million ≈ $3.77 Million |
AU$-1.74 Million ≈ $-1.23 Million |
-0.327x | -3.21% |
| 1996-06-30 | AU$3.83 Million ≈ $2.71 Million |
AU$-1.22 Million ≈ $-859.69K |
-0.317x | +2.21% |
| 1995-06-30 | AU$2.07 Million ≈ $1.47 Million |
AU$-672.00K ≈ $-475.48K |
-0.324x | -44.64% |
| 1994-06-30 | AU$2.09 Million ≈ $1.48 Million |
AU$-469.00K ≈ $-331.85K |
-0.224x | -3.14% |
| 1993-06-30 | AU$1.62 Million ≈ $1.14 Million |
AU$-351.00K ≈ $-248.35K |
-0.217x | -32.60% |
| 1992-06-30 | AU$1.63 Million ≈ $1.15 Million |
AU$-267.00K ≈ $-188.92K |
-0.164x | -7.51% |
| 1991-06-30 | AU$1.29 Million ≈ $914.88K |
AU$-197.00K ≈ $-139.39K |
-0.152x | -- |
About Opthea Ltd
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more